Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study…

Continue Reading

News Source: medicalxpress.com